<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2121">
  <stage>Registered</stage>
  <submitdate>26/09/2008</submitdate>
  <approvaldate>26/09/2008</approvaldate>
  <nctid>NCT00762762</nctid>
  <trial_identification>
    <studytitle>Investigate Plaque and Gingival Index</studytitle>
    <scientifictitle>Investigate Plaque and Gingival Index</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004000685</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Periodontitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Triclosan and fluoride
Treatment: drugs - Fluoride

Active Comparator: A - 

Placebo Comparator: B - 


Treatment: drugs: Triclosan and fluoride
Brush twice daily

Treatment: drugs: Fluoride
swished twice daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c Levels in Blood - Blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). This test measures the glycated hemoglobin in the blood.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>High Sensitivity CRP (C-Reactive Protein) - CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>C-Peptide - C-Peptide levels in blood indicate whether or not a person is producing insulin</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>IL-6 (Interleukin - 6) - Levels of Interleukin - 6 (GCF IL-6) found in blood drawn from subjects. Indication of systemic inflammation in the body.(weight in picagrams)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>TNF-a (Tumor Necrosis Factor - Alpha) - Blood drawn from subjects to determine the level of TNF-a (Tumor necrosis factor - alpha). TNF-a is a pleiotropic inflammatory cytokine involved in systemic inflammation.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes with poor glycaemic control as evidenced by random blood glucose of
             &gt;200mg/dl.

          -  Minimum of 16 teeth

          -  Chronic periodontitis as indicated by periodontal probing depths &gt;4mm on at least 6
             teeth</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any condition requiring antibiotic cover for dental treatment

          -  Other serious illness</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>46</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Republic of Marshall Islands - Queensland</hospital>
    <postcode> - Queensland</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Colgate Palmolive</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Clinical research study to determine the anti-plaque efficacy of commerical dentifrices.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00762762</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregory Seymour, BDS, PhD</name>
      <address>Otago University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>